FDA Drug · D-0895-2023

Losartan Potassium Tablets, USP, 25 mg, 1000 film coated tablets per bottle, Rx Only, Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108, SIDCO Pharmaceutical Complex, Alathur, Kanchipuram- 603 110, Tamilnadu, India, NDC 64380-933-08

Class II · Terminated

Presence of Foreign Substance: Presence of a small piece of blue plastic embedded in the tablet.

Affected lots / codes — check yours against thisLot#: 7901903A, exp. date 04/2024

Recalling firm: Strides Pharma Inc., East Brunswick, NJ
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 2,700 HDPE Bottles
Distribution: Nationwide in the USA.
Recall initiated: June 26, 2023
Classified: July 6, 2023
Terminated: May 15, 2024
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0895-2023%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

See every recall for this brand: Is LOSARTAN POTASSIUM recalled? →

Check this brand across all 8 databases →